Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Recently, it was reported that when vancomycin levels are determined after port sampling, levels can be falsely increased potentially leading to wrong dose adjustments.
The investigators conducted an in vitro experiment using several central venous port devices, in which different flushing techniques were evaluated yielding residual vancomycin levels of less than 0.5 mg/L.
In this study, the investigators want to evaluate this flushing technique in vivo in 15 patients admitted with catheter-related infection and treated with systemic vancomycin and vancomycin antibiotic lock.
The purpose is to assess if correct flushing can avoid spurious vancomycin levels obtained via port sampling.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| vancomycin cohort |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| blood levels | Procedure |
|
| Measure | Description | Time Frame |
|---|---|---|
| comparison of central (via port device) and peripherally obtained vancomycin levels: the difference, when using the new flushing technique, is allowed to be maximally 0.5 mg/L | central and peripheral vancomycin levels will be obtained during steady state: this means starting from the 4th dose (= day 2) of vancomycin treatment. Vancomycin is usually given during 14 days after the last positive blood culture. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult patients admitted for catheter related infection with methicillin-resistant coagulase-negative staphylococci (MR-CNS) and treated with systemic vancomycin in combination with vancomycin antibiotic lock via central venous port device.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Isabel Spriet, PharmD PhD | Contact | 0032 16 34 30 80 | isabel.spriet@uzleuven.be | |
| Jan Verhaegen, MD PhD | Contact | 0032 16 33 22 11 | jan.verhaegen@uzleuven.be |
| Name | Affiliation | Role |
|---|---|---|
| Isabel Spriet, PharmD PhD | Pharmacy Dpt, University Hospitals Leuven | Principal Investigator |
| Jan Verhaegen, MD PhD | Medical Diagnostic Sciences, University Hospitals Leuven | Study Chair |
Not provided
Not provided
| ID | Term |
|---|---|
| D055499 | Catheter-Related Infections |
| ID | Term |
|---|---|
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D000089382 | Oxygen Saturation |
| ID | Term |
|---|---|
| D008660 | Metabolism |
Not provided
Not provided
Not provided
Not provided
Not provided
blood samples
| Hans Prenen, MD PhD |
| Digestive ONcology, University Hosptials Leuven |
| Study Chair |
| Willy Peetermans, MD PhD | Internal Medicine, University Hospitals Leuven | Study Chair |
| Ludo Willems, PharmD PhD | Pharmacy Dpt., University Hosptials Leuven | Study Chair |